阿伯西普联合以氟尿嘧啶为基础化疗治疗晚期大肠癌研究.pptVIP

读书报告 汇报人：罗娜 Background Patients with metastatic colorectal cancer (mCRC) previously-treated with oxaliplatin benefit significantly from the addition of aflibercept to FOLFIRI in relation to overall survival, progression-free survival and response rate. typically regimen Treatment of metastatic colorectal cancer (mCRC) typically involves a fluoropyrimidine-based hemotherapy regimen, combining infusional fluorouracil (5-FU) and leucovorin with oxaliplatin (FOLFOX regimen) or rinotecan (FOLFIRI regimen). FOLFOX+bevacizumab In the E3200 study, it was shown that the addition of bevacizumab to FOLFOX improves survival duration for patients with previously treated mCRC who had not received first-line treatment with oxaliplatin or bev-acizumab. FOLFIRI+aflibercept VEGF Trap (aflibercept) with irinotecan in colorectal cancer after failure of oxaliplatin regimen (VELOUR) was the first randomised, placebo-controlled, phase III trial to show a statistically significant improvement in OS, progression-free survival (PFS) and response rate (RR) for an anti-angiogenic in combination with FOLFIRI compared with FOLFIRI alone in a prior oxaliplatin-treated population. FOLFIRI+aflibercept Patients receiving FOLFIRI plus aflibercept had a median OS of 13.5 months versus 12.0 months for patients receiving FOLFIRI plus placebo, representing a relative reduction in the risk of death of 18.3% for the aflibercept arm compared with the placebo arm. Patients?and Methods The results for efficacy and safety over the time course of the VEGF Trap (aflibercept) with irinotecan in colorectal cancer after failure of oxaliplatin regimen trial were analysed based on data from 1226 patients randomised to receive FOLFIRI plus either aflibercept (n = 612) or placebo (n = 614). Hazard ratios (HR) by 6-month time period were estimated using a piecewise Cox proportional hazard model. Severity of adverse events (AEs) was graded using National Cancer Institute Common Terminology Criteria, version 3.0. Fig